Navigation Links
Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohn's Disease
Date:8/27/2012

BOTHELL, Wash., Aug. 27, 2012 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease.

The milestone payment is part of the collaboration between Alder and Bristol-Myers Squibb that was formed in 2009 for the development of ALD518/BMS-945429. Under the collaboration agreement, Alder granted to Bristol-Myers Squibb worldwide exclusive rights to develop and commercialize ALD518/BMS-945429 for all potential clinical uses, with the exception of cancer treatment and cancer supportive care, which are rights retained by Alder.

"We have long believed that ALD518/BMS-945429 would have potential in a large number of disease areas, and today we are excited to see Bristol-Myers Squibb advancing into another area of tremendous unmet need, Crohn's disease," said Randall Schatzman, Ph.D., president and chief executive officer of Alder Biopharmaceuticals. "We look forward to continuing with the clinical investigation in multiple areas through this partnership, including in the ongoing Phase 2b clinical trial in rheumatoid arthritis, as well as in cancer treatment and cancer supportive care on our own."

About Alder Biopharmaceuticals

Alder BioPharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular and autoimmune and inflammatory disease areas. The company's second therapeutic program, an investigational monoclonal antibody for migraine, ALD403, inhibits a well-validated molecule shown to trigger migraine attacks, calcitonin gene-related peptide (CGRP), and is now in clinical trials. ALD518 is Alder's investigational monoclonal antibody to the pro-inflammatory cytokine IL-6. Alder is developing ALD518 in Phase
'/>"/>

SOURCE Alder BioPharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
3. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
4. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
8. GeNO LLC Receives Four Additional Patents for Inhaled Nitric Oxide Delivery
9. Patient Advocate Foundation Receives Significant Support to Aid Non-Squamous Non-Small Cell Lung Cancer Patients through the Co-Pay Relief Program
10. UTHealth Receives FDA Approval To Market New Coronary Flow Reserve Quantification Software
11. Neusoft Positron Medical Systems Receives ISO Certification and CE Mark for their Attrius PET System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and RALEIGH, N.C. , Dec. ... LLC (CTMC), and Integrated Clinical Trial Services, LLC ... retention for clinical trials announce that they have ... Marketing Services (i-CTMS). i-CTMS will provide a broad ... pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind alle ... SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 ... besuchen. Diese Tagung soll dazu ... Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, die ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... addition of the "Electrocardiogram (ECG) Devices - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... reach US$330 million by 2016. The North ... the global market share while Europe ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... 2012 The kids are outside playing soccer, baseball, or ... next thing parents know, there is a trip to the ... can heal properly is the refined work of physicians and ... child,s day-to-day life while injured. A common problem parents face ...
... this year,s Annual Scientific Meeting of the American ... Grunenthal will present results from clinical studies utilizing ... INTAC™ is designed to be crush-resistant and to ... INTAC™ to prescription opioid drugs is considered an ...
Cached Medicine Technology:Warm Weather Means Active Children May Be Prone To More Injuries 2INTAC™ Technology Combats Misuse of Extended Release Drugs 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... cancers, especially leukemia, have improved greatly in the ... seem to face many health,and lifestyle challenges as ... and treatment methods, many continue to struggle with ... of life, according to a,study prepublished online in ...
... March 31 Hillenbrand,Industries, Inc. (NYSE: HB ) ... previously announced cash tender offer to purchase any,and all ... (CUSIP No.,431573AD6). The tender offer was made pursuant to ... to Purchase") and the related Letter of,Transmittal, which set ...
... 31 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... under which it may sell up to $50,million of ... a,24-month period. Alexza is not obligated to utilize any ... into and consummate other equity and,debt financing transactions., ...
... a Solid Foundation for Marriage and Family, ... offering an innovative program, "Supporting Healthy Marriage" to ... The purpose,of the program, administered by University Behavioral ... build a solid foundation,for marriage and family through ...
... to Consulting Addresses Fears That Lawyers Have That, ... Accurately Describes The Business, WASHINGTON, March 31 ... announced it is,becoming the first in the nation ... attorney. It had previously been the first in ...
... reduce lead dust during renovations , , MONDAY, March ... issued new rules designed to protect children from ... to homes and buildings. , Starting in ... standards" that are designed to reduce potential exposure ...
Cached Medicine News:Health News:Childhood Leukemia Survivors Struggle With Long-Term Comorbidities 2Health News:Childhood Leukemia Survivors Struggle With Long-Term Comorbidities 3Health News:Childhood Leukemia Survivors Struggle With Long-Term Comorbidities 4Health News:Hillenbrand Industries, Inc. Announces Expiration and Final Results of its Previously Announced 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces Expiration and Final Results of its Previously Announced 'Any and All' Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009 3Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 2Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 3Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 4Health News:'Supporting Healthy Marriage' Program Offered by Montefiore 2Health News:Leventhal Weight Loss Incorporated Becomes First in the Nation Executive Weight Loss Consulting Service for Attorneys by an Attorney 2Health News:New Rule Seeks to Protect Kids From Lead Paint 2
Straight heavy shafts with 7 mm tying surface. Wide serrated handle, polished finish. Overall length 4.2 inches....
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Straight shafts. Overall length 3.9 inches....
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Medicine Products: